Appointment of Joint Broker

Kromek Group PLC

24 July 2023

 

24 July 2023

Kromek Group plc

("Kromek" or the "Group")

Appointment of Joint Broker

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces the appointment of Cenkos Securities plc as joint broker to the Group with immediate effect. finnCap Ltd will continue to act as the Group's nominated adviser and joint broker.

For further information, please contact: 

Kromek Group plc
Arnab Basu, CEO  Paul Farquhar, CFO	[phone]
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash/Seamus Fricker/George Dollemore - Corporate Finance  Tim Redfern/Charlotte Sutcliffe - ECM	[phone]
Cenkos Securities plc (Joint Broker)
Giles Balleny - Corporate Finance Michael Johnson/Tamar Cranford-Smith - Sales	[phone]
Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury/Henry Gamble	[phone]

Kromek Group plc 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

END